Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Chantale Bernatchez(BMC Software (United States)), Adi Diab(Cleveland Clinic), Ej Liao(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Natalie Jackson(The University of Texas MD Anderson Cancer Center), I. Gergel(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Michael J. Imperiale(University of Michigan), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Ernesto Iacucci(Nektar Therapeutics (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Mary Tagliaferri(Nektar Therapeutics (United States)), Michael E. Hurwitz(Yale University), Christie Fanton(Nektar Therapeutics (United States)), Patrick Hwu(Moffitt Cancer Center), Salah Eddine Bentebibel(Texas Medical Center), Harriet M. Kluger(Yale Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Mario Sznol(Yale University)
Cited by 23
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k